Why test?^{6, 8}



Adhere to ESMO guideline recommendations, which base the use of cytotoxics and biologicals on molecular profile



Gain a deeper knowledge of the impact and clinical relevance of mutations



Promote enrolment of patients into clinical trials with new targeted approaches



Improve outcomes for patients with mCRC



VanCutsem E, *et al. Ann Oncol* 2016;27:1386–422. Cervantes A, *et al. Ann Oncol* 2023;34(1):10-32.

Test for mutations today

© 2023 Pierre Fabre, all rights reserved. Pierre Fabre Singapore Pte. Ltd. 96 Robinson Road, SIF Building, #14-03, Singapore 068899. SG_BMC_2306_04. Material Approved: June 2023